Expertise in
19
conditions

Dr. Ashkan Emadi

Hematology
West Virginia University Hospitals
1 Medical Center Dr, 
Morgantown, WV 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
26 Years of Experience
Expertise in
19
conditions
West Virginia University Hospitals
1 Medical Center Dr, 
Morgantown, WV 

Overview

Ashkan Emadi is a Hematologist practicing medicine in Morgantown, West Virginia. He has been practicing medicine for over 26 years.

Dr. Emadi is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Acute Promyelocytic Leukemia, Acute Lymphoblastic Leukemia (ALL), Bone Marrow Aspiration, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 110 peer reviewed articles and participating in 9 clinical trials. Dr. Emadi is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in MD

Hospital Affiliations

University Of Maryland Medical Center
Uniontown Hospital
United Hospital Center, Inc
West Virginia University Hospitals, Inc

Languages Spoken

English
Farsi

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
The Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

West Virginia University Hospitals
1 Medical Center Dr, Morgantown, WV 26506

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
Enrollment Status: Recruiting
Publish Date: September 02, 2026
Intervention Type: Biological, Drug, Procedure, Other
Study Drugs: Allopurinol, Cytarabine, Daunorubicin Hydrochloride, Vincristine Sulfate, Dexamethasone, Pegylated L-Asparaginase, Methotrexate, Cyclophosphamide, Mercaptopurine, Rituximab, Doxorubicin, Thioguanine, Inotuzumab
Study Phase: Phase 3
A Phase 1 Trial of Calaspargase Pegol-mknl in Combination With High Dose Cytarabine and Idarubicin in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase 1 Trial of Calaspargase Pegol-mknl in Combination With High Dose Cytarabine and Idarubicin in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Drug
Study Drug: Calaspargase pegol-mknl
Study Phase: Phase 1
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure
Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: October 07, 2025
Intervention Type: Drug
Study Drugs: Venetoclax, Pegcrisantaspase
Study Phase: Phase 1
A Pilot Study of Sorafenib in Patients With Acute Myeloid Leukemia as Peri-Transplant Remission Maintenance
A Pilot Study of Sorafenib in Patients With Acute Myeloid Leukemia as Peri-Transplant Remission Maintenance
Enrollment Status: Completed
Publish Date: April 02, 2024
Intervention Type: Procedure, Drug
Study Phase: Phase 1
A Phase 1/2, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 DART® Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory AML or Intermediate-2/High Risk Myelodysplastic Syndrome (MDS)
A Phase 1/2, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 DART® Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory AML or Intermediate-2/High Risk Myelodysplastic Syndrome (MDS)
Enrollment Status: Terminated
Publish Date: January 30, 2024
Intervention Type: Biological, Drug
Study Drug: Flotetuzumab
Study Phase: Phase 1/Phase 2
A Phase 1 Trial of Indoximod in Combination With Idarubicin and Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
A Phase 1 Trial of Indoximod in Combination With Idarubicin and Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: June 04, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase I Study of L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) in Combination With the CALGB Regimen During Induction and Consolidation Phases in the Treatment of Adult Patients With Acute Lymphoblastic Leukemia and Lymphoma
A Phase I Study of L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) in Combination With the CALGB Regimen During Induction and Consolidation Phases in the Treatment of Adult Patients With Acute Lymphoblastic Leukemia and Lymphoma
Enrollment Status: Terminated
Publish Date: July 05, 2018
Intervention Type: Drug
Study Phase: Phase 1
1336GCC: Open-Label, Single-Arm PK Study of IV Erwinaze (Asparaginase Erwinia Chrysanthemi) to Find the Dose With Acceptable Therapeutic and Safety Profile in Adults With Acute Myeloid Leukemia With or Without Isocitrate Dehydrogenase Mutations
1336GCC: Open-Label, Single-Arm PK Study of IV Erwinaze (Asparaginase Erwinia Chrysanthemi) to Find the Dose With Acceptable Therapeutic and Safety Profile in Adults With Acute Myeloid Leukemia With or Without Isocitrate Dehydrogenase Mutations
Enrollment Status: Completed
Publish Date: March 12, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 8 Less Clinical Trials

110 Total Publications

A systematic review of artificial intelligence in radiotherapy associated cardiovascular toxicity.
A systematic review of artificial intelligence in radiotherapy associated cardiovascular toxicity.
Journal: Cardio-oncology (London, England)
Published: March 04, 2026
Similar Doctors
Expertise in
33
conditions
Expertise in
33
conditions
Referral may be required

Mon Health Cancer Center

1200 J D Anderson Dr, 
Morgantown, WV 
 (0.9 miles away)
304-598-6560
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Michael Craig is a Hematologist practicing medicine in Morgantown, West Virginia. Dr. Craig is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, Acute Myeloblastic Leukemia without Maturation, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Craig is currently accepting new patients.

Expertise in
9
conditions
Expertise in
9
conditions
Referral may be required
Before you request

Classical Hematology

3601 Fifth Ave, Falk Building, 3rd Floor, 
Pittsburgh, PA 
 (54.6 miles away)
412-586-9875
Languages Spoken:
English, Italian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Enrico M. Novelli, MD, is a classical (benign) hematologist, the Chief of the Section of Benign Hematology, and the medical director of the UPMC Adult Sickle Cell Disease Program. Board-certified in hematology, Dr. Novelli received his medical degree from the University of Milan, Italy. He completed his residency in internal medicine and fellowship in hematology-oncology at UPMC. Dr. Novelli specializes in sickle cell anemia and hemoglobinopathies. Dr. Novelli is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemolytic Anemia, and Hemoglobinopathy. Dr. Novelli is board certified in American Board Of Internal Medicine. Dr. Novelli is currently accepting new patients.

Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required

Office

40 Medical Park Ste 300, 
Wheeling, WV 
 (46.6 miles away)
304-243-6442
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Bhavana Bhatnagar is a Hematologist practicing medicine in Wheeling, West Virginia. Dr. Bhatnagar is highly rated in 24 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Bhatnagar is currently accepting new patients.

Frequently Asked Questions about Dr. Ashkan Emadi

How do I make an appointment with Dr. Ashkan Emadi?

You can book an appointment with Dr. Ashkan Emadi by calling their office at 304-598-4500. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ashkan Emadi a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ashkan Emadi is classified as an Elite expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ashkan Emadi specialize in?

While Dr. Ashkan Emadi is a Hematology, they have specific expertise in Acute Myeloid Leukemia (AML), Acute Promyelocytic Leukemia, and Acute Lymphoblastic Leukemia (ALL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Ashkan Emadi participate in research or clinical trials?

Yes. Dr. Ashkan Emadi has published 110 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dr. Ashkan Emadi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Ashkan Emadi accept my insurance?

Dr. Ashkan Emadi accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 304-598-4500 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Emadi's expertise for a condition
ConditionClose
View All 12 Advanced Conditions
View All 39 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile